Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia
Status:
Completed
Trial end date:
2018-09-20
Target enrollment:
Participant gender:
Summary
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol
(LDL-C) levels after a 12-week period of treatment in adults with primary
hypercholesterolemia;
To determine the safety of HS-25 (20mg) in subjects with LDL-C